{"id":"14308ab3-647a-4007-815c-2b605e1b5a50","url":"content/14308ab3-647a-4007-815c-2b605e1b5a50","title":"Economic evidence","outline":"/publication/75bfaa02-cc71-4a79-a7dd-dbc47541edea/outline","content":{"mime":"application/xml","data":"<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<!-- content-type_s: --><!-- Generated by cjs2htmlbase.xsl--><div data-ot-plugin=\"com.congility.html\" lang=\"en\" role=\"main\" xmlns:astX=\"http://www.astoriasoftware.com/translation\"><div class=\"topic evidence commentable-section\" data-annot-id=\"topic.dita_10221701-33c9-406f-b0da-71560491b10f\" id=\"topic.dita_10221701-33c9-406f-b0da-71560491b10f\"><article aria-labelledby=\"ariaid-title1\" role=\"article\">\n  \n  <div class=\"body evidence-text\">\n    <p class=\"p\">We found adjuvant trastuzumab to be cost effective based on evidence from 10 good-quality economic evaluations. </p>\n  </div>\n</article></div></div>"},"metadata":{},"solr":{"custom":{},"doc":{"href_s":"SD00835085","url_s":"content/14308ab3-647a-4007-815c-2b605e1b5a50","title_s":"Economic evidence","nextTopic_s":"42af8b80-26ed-418b-b569-5947b243c365","prevTopic_s":"764e94a3-c1c9-4eb6-95b4-89dc1d81ff93"},"nice":{"nice_infotype_s":"evidence","nice_guideline-id_s":"","nice_content-id_s":"","nice_content-type_s":"","nice_condition-disease_s":"BreastCancer"}},"contentObject":{"publicationuuid":"75bfaa02-cc71-4a79-a7dd-dbc47541edea","contentuuid":"14308ab3-647a-4007-815c-2b605e1b5a50","contentjoinuuid":"83e60dc1-df64-437a-9c75-c286a5aa1f6b","contentjoinuuids":["83e60dc1-df64-437a-9c75-c286a5aa1f6b","b6411394-b182-48a0-932b-feab3de553ac"],"publicationjoinuuid":"356cbf6a-a380-418a-9856-781ae39f6dca"}}